Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Medical Center Groningen
About this trial
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
Fit for systemic treatment (PS 0-2) according to standard of care.
No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
Disqualifiers
Prior/concomitant therapy for stage IV disease.
Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
Trial design
Design model
Single group
Treatments tested in this trial
MRI
Diagnostic testMRI scan of the brain
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Screening populationExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Clinical value of the MRI
Clinical value of the MRI evaluated by the treating thoracic oncologist and assessed by questionnaires completed on three timepoints.
Time frame
up to 6 months after the MRISponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov